Company Analysis
Sign in

Molecular Partners AG (MOLN)

Nasdaq: MOLN · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.3
◀ Past 5.7● Present 5.4▶ Future 5.0
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of Swiss francs (CHF), as filed; per-share figures in Swiss francs; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Report filedMar 12, 2026Mar 6, 2025Mar 14, 2024Mar 9, 2023Mar 15, 2022··
Revenue04,9707,038189,5569,3309,34420,383
Research and development40,19448,60448,78450,74955,71856,07543,498
Selling, general and administrative15,24117,58319,36222,23817,45411,59513,545
Total operating expenses58,12466,18768,14672,98773,17267,67057,043
Operating income-58,124-61,217-61,108116,613-63,418-58,326-36,660
Finance costs5,047385,1556195564,8161,210
Finance income1,5227,2144,2791,8591913671,599
Net finance income (costs)-3,5257,176-8761,240-365-4,449389
Income before income taxes-61,649-54,041-61,984117,853-63,783-62,775-36,271
Income tax expense22002-1117
Net income-61,651-54,043-61,984117,853-63,785-62,764-36,288
Earnings per share, basic-1.65-1.59-1.893.63-2.06-2.51-1.69
Earnings per share, diluted-1.65-1.59-1.893.54-2.06-2.51-1.69
Weighted average shares, basic37,271,28134,032,54432,770,66532,469,95731,005,17125,000,65221,413,375
Weighted average shares, diluted37,271,28134,032,54432,770,66533,265,56731,005,17125,000,65221,413,375
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:RevenueFromContractsWithCustomers
ifrs-full:Revenue
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyifrs-full:SellingGeneralAndAdministrativeExpense
Total operating expenses the running costs togetherifrs-full:OperatingExpense
Operating income profit from running the business, before interest and taxifrs-full:ProfitLossFromOperatingActivities
Finance costs what its borrowing costifrs-full:FinanceCosts
Finance income what its cash and investments earnedifrs-full:FinanceIncome
Net finance income (costs) interest earned less interest paid, outside the businessifrs-full:FinanceIncomeCost
Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton MOLN · research, not advice